Posts

Posted on

Cronos Appoints Anna Shlimak as Chief Financial Officer

TORONTO, March 19, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos’ Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition.

Ms. Shlimak has been an integral part of Cronos’ leadership team for the last seven years, playing a key role in shaping the Company’s strategy, operational efficiencies, and engagement with the financial and investment community. During her tenure, she has led many strategic initiatives including cost optimization, revenue growth, and building Cronos’ corporate brand, which have positioned the Company for long-term success.

“I am incredibly pleased Anna Shlimak is stepping into the Chief Financial Officer role,” said Mike Gorenstein, President and Chief Executive Officer, Cronos. “Anna has been an essential part of our senior leadership team. With a deep understanding of our business and a proven track record of driving financial performance, operational efficiency and strategic growth, Anna is the ideal leader to help drive our financial strategy and next phase of growth.

Mr. Gorenstein continued, “I want to sincerely thank James for his contributions to Cronos. He played an important role in improving our finance functions and has worked to build a robust Finance team. His commitment to Cronos has been essential and I thank James for everything he’s contributed to the Company and wish him all the best in his future endeavors.”

Mr. Holm said, “I’m incredibly proud of what we’ve accomplished over the past two and a half years and look forward to watching the Cronos team continue to deliver strong results. Under Anna’s leadership, I’m confident the Company will continue to grow and lead the cannabis industry on a global scale.”

Ms. Shlimak said, “I am honored to step into the role of CFO and continue working alongside our talented teams. Cronos is committed to building exceptional cannabis brands and products that enhance experiences, and I am excited to lead our financial and strategic growth as we continue to expand and drive performance. As we enter the next phase of growth, I look forward to driving long-term value for our shareholders, employees, and consumers.”

About Anna Shlimak

Anna recently served as the Company’s Chief Strategy Officer and was responsible for managing and directing the organization’s corporate strategy, investor relations, communications, government affairs, and information systems departments. Prior to joining Cronos, Anna was the Head of Investor Relations at Quest Partners LLC, a research-driven alternative investment firm. Anna was responsible for business development, investor reporting, marketing, and communication initiatives for the fund. Before that, Anna held a range of roles at the New York Stock Exchange in both the New York and London offices. She received a Master of Business Administration from Columbia Business School and holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania.

About Cronos Group Inc.

Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

Forward-looking Statements

This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about transition plans with respect to the Company’s Chief Financial Officer role; the Company’s growth, industry leadership, success and financial strategy; long-term value for the Company’s shareholders, employees and consumers; and the Company’s intention to build an international iconic brand portfolio and develop disruptive intellectual property by advancing cannabis research, technology and product development. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

Media Relations Contact:

Emily Whalen
Communications
Tel: (416) 504-0004
[email protected]

Investor Relations Contact:

Tel: (416) 504-0004
[email protected]



Posted on

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

Webcast and Conference Call

Date/Time: Thursday, March 27, 2025 @ 5:00 PM ET
Webcast: https://edge.media-server.com/mmc/p/5r5hkcqq
Dial-in Link: https://register-conf.media-server.com/register/BI74b28f5ee02c4c1c89a835bfb6bdc1c8
   

Participants are encouraged to pre-register any time before the call through the dial-in link. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company’s website under the ‘For Investors’ section. The webcast will be available on the Company’s website for 90 days following the live call.

About Plus Therapeutics

Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

These statements include, without limitation, statements under the heading Upcoming Events and Expected Milestones, and statements regarding the following: CLIA compliance certification of the Company’s Houston-based clinical laboratory; the potential promise of rhenium (186Re) obisbemeda; expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates; the Company’s clinical trials, including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC clinical trials; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts;; development and utility of CNSide leptomeningeal metastases diagnostic test.

The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, including the ability of the Company to come into compliance with The Nasdaq Capital Market listing requirements; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact

Jules Abraham
Managing Director, Communications
CORE IR
[email protected]



Posted on

Herc Holdings Commences Tender Offer for All Outstanding Shares of H&E Equipment Services

Herc Holdings Commences Tender Offer for All Outstanding Shares of H&E Equipment Services

H&E Shareholders to Receive $78.75 in Cash and 0.1287 shares of Herc Common Stock Per H&E Share

BONITA SPRINGS, Fla.–(BUSINESS WIRE)–
Herc Holdings Inc. (NYSE: HRI) (“Herc” or “the Company”), one of North America’s leading equipment rental suppliers, today announced that its wholly-owned subsidiary HR Merger Sub Inc. (“Merger Sub”) has commenced the previously announced tender offer (the “Offer”) to acquire all of the outstanding shares of H&E Equipment Services, Inc. (NASDAQ: HEES) (“H&E”) common stock for $78.75 in cash and 0.1287 shares of Herc common stock for each H&E share, in each case without interest. The Offer is being made pursuant to the previously announced merger agreement, dated February 19, 2025, between Herc, Merger Sub and H&E.

The Offer will expire at one minute past 11:59 p.m. Eastern Time, on April 15, 2025, unless extended or earlier terminated, in each case in accordance with the terms of the merger agreement. The Offer is subject to the majority of H&E’s shares being tendered into the Offer, the receipt of customary regulatory approvals and other customary closing conditions. Herc will finance the Offer through a combination of available cash on hand, proceeds from the sale of marketable securities and funds drawn through its credit facility, which was amended on March 11, 2025, in connection with the H&E transaction. Following completion of the Offer, Herc will acquire all remaining shares not tendered in the Offer through a second-step merger at the same price as in the Offer. The transaction is expected to close mid-year 2025.

Herc will file today with the U.S. Securities and Exchange Commission (the “Commission”) a tender offer statement on Schedule TO, including an Offer to Purchase and related Letter of Transmittal, which will include the terms of the Offer, along with a Registration Statement on Form S-4. Additionally, H&E will file today a Solicitation/Recommendation Statement on Schedule 14D-9 with the Commission containing the recommendation of its Board of Directors that H&E shareholders tender their shares into the Offer. The Schedule TO, Form S-4, Schedule 14D-9, Letter of Transmittal and other Offer materials can be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting DF King, the information agent for the Offer, as described in the Offer documents.

Herc Advisors

Guggenheim Securities, LLC is serving as lead financial advisor. Credit Agricole Securities (USA) Inc. is serving as co-financial advisor, with Credit Agricole Corporate and Investment Bank serving as lead financing bank. Simpson Thacher & Bartlett LLP is serving as legal advisor. Joele Frank, Wilkinson Brimmer Katcher is serving as strategic communications advisor.

About Herc Holdings Inc.

Founded in 1965, Herc Holdings Inc., which operates through its Herc Rentals Inc. subsidiary, is a full-line rental supplier with 451 locations across North America, and 2024 total revenues of approximately $3.6 billion. We offer products and services aimed at helping customers work more efficiently, effectively, and safely. Our classic fleet includes aerial, earthmoving, material handling, trucks and trailers, air compressors, compaction, and lighting equipment. Our ProSolutions® offering includes industry-specific, solutions-based services in tandem with power generation, climate control, remediation and restoration, pumps, and trench shorting equipment as well as our ProContractor professional grade tools. We employ approximately 7,600 employees, who equip our customers and communities to build a brighter future. Learn more at www.HercRentals.com and follow us on Instagram, Facebook and LinkedIn.

Additional Information and Where to Find It

This communication is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for any offer materials that Herc and Merger Sub, will file with the Commission. On March 19, 2025, Herc and Merger Sub will file a tender offer statement on Schedule TO and Herc will file a registration statement on Form S-4. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO EXCHANGE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER MATERIALS) AND THE FORM S-4 WILL CONTAIN IMPORTANT INFORMATION. H&E STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF H&E SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING EXCHANGING THEIR SECURITIES. The tender offer materials will be made available to holders of H&E stock at no expense to them. The tender offer materials will be made available for free at the SEC’s web site (http://www.sec.gov). Additional copies may be obtained for free by contacting either Herc or H&E. Copies of the documents filed with the SEC by H&E will be available free of charge on H&E’s website at https://investor.he-equipment.com/. Copies of the documents filed with the SEC by Herc will also be available free of charge on the Company’s website at https://ir.hercrentals.com/. In addition to the tender offer materials, Herc and H&E file annual, quarterly and current reports, proxy statements and other information with the SEC, which are available to the public at the SEC’s web site (http://www.sec.gov).

Cautionary Note Regarding Forward Looking Statements

This communication includes “forward-looking statements,” within the meaning of Section 21E of the Securities Exchange Act, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements related to the Company and the proposed acquisition of H&E by the Company that involve substantial risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements in this communication include, the Company’s plans, objectives, expectations and intentions, the financial condition, results of operations and business of each of the Company and H&E, and the anticipated timing of closing of the proposed transaction. Forward-looking statements are generally identified by the words “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” “forecasts,” “looks,” and future or conditional verbs, such as “will,” “should,” “could” or “may,” as well as variations of such words or similar expressions. All forward-looking statements are based upon our current expectations and various assumptions and apply only as of the date of this communication. Our expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that our expectations, beliefs and projections will be achieved or that the completion and anticipated benefits of the proposed transaction can be guaranteed, and actual results may differ materially from those projected. You should not place undue reliance on forward-looking statements.

There are a number of risks, uncertainties and other important factors that could cause our actual results to differ materially from those suggested by our forward-looking statements, including, but not limited to, (i) the possibility that the sufficient number of H&E’s shares are not validly tendered into the tender offer to meet the minimum condition; (ii) the Company’s ability to implement its plans, forecasts and other expectations with respect to H&E’s business after the completion of the proposed transaction and realized expected synergies; (iii) the ability to realize the anticipated benefits of the proposed transaction, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; (iv) the Company and H&E may be unable to obtain regulatory approvals required for the proposed transaction or may be required to accept conditions that could reduce the anticipated benefits of the proposed transaction as a condition to obtaining regulatory approvals; (v) the length of time necessary to consummate the proposed transaction may be longer than anticipated; (vi) problems may arise in successfully integrating the businesses of the Company and H&E, including, without limitation, problems associated with the potential loss of any key employees, customers, suppliers and other counterparties of H&E; (vii) the proposed transaction may involve unexpected costs, including, without limitation, the exposure to any unrecorded liabilities or unidentified issues during the due diligence investigation of H&E or that are not covered by insurance, as well as potential unfavorable accounting treatment and unexpected increases in taxes; (viii) the Company’s business may suffer as a result of uncertainty surrounding the proposed transaction, any adverse effects on our ability to maintain relationships with customers, employees and suppliers; (ix) the occurrence of any event, change to other circumstances that could give rise to the termination of the merger agreement, the failure of the closing conditions included in the merger agreement to be satisfied, or any other failure to consummate the proposed transaction; (x) any negative effects of the announcement of the proposed transaction or the financing thereof on the market price of the Company common stock or other securities; and (xi) the industry may be subject to future risks including those set forth in the “Risk Factors” section in the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and in the other filings with the SEC by the Company. The foregoing list of factors is not exhaustive. Investors should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of the Company, including those described in the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and in the other filings with the SEC by the Company. All forward-looking statements are expressly qualified in their entirety by such cautionary statements. We undertake no obligation to update or revise forward-looking statements that have been made to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events.

Leslie Hunziker

Senior Vice President

Investor Relations, Communications & Sustainability

[email protected]

239-301-1675

Joele Frank, Wilkinson Brimmer Katcher

[email protected]

T.J. O’Sullivan / 415-378-6841

Maggie Carangelo / 917-865-2500

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Other Construction & Property Retail Commercial Building & Real Estate Construction & Property Specialty

MEDIA:

Logo
Logo
Posted on

Real’s February Agent Survey: Inventory Rises as Listing Times Lengthen

Real’s February Agent Survey: Inventory Rises as Listing Times Lengthen

Transaction Growth and Agent Optimism Indexes Ease but Remain Near Recent Highs

TORONTO & NEW YORK–(BUSINESS WIRE)–
The Real Brokerage Inc. (NASDAQ: REAX, “Real”), a technology platform reshaping real estate for agents, home buyers and sellers, today released results from its February 2025 Agent Survey. The findings indicate that housing inventory is rising in many markets, leading to longer listing times and increased price reductions as sellers adjust expectations. Meanwhile, Real’s Agent Optimism and Transaction Growth indexes moderated in February, though remain elevated relative to last year.

“Higher inventory levels are giving buyers more options and greater negotiating power, but affordability still remains the biggest hurdle in today’s market,” said Tamir Poleg, Chairman and CEO of Real. “While our Transaction Growth Index softened slightly from last month, the overall market continues to show signs of stabilization.”

“As more homes come on to the market agents are advising sellers to set realistic price expectations and, in some cases, invest in upgrades to attract buyers,” said Sharran Srivatsaa, President of Real. “Sellers who overprice their homes are seeing longer days on market, while those who price more competitively or enhance their listings with staging and cosmetic improvements are securing more offers and faster sales.”

Key Survey Findings: Market Trends and Insights

  • Transaction Growth Index Slips Back into Contraction: Real’s Transaction Growth Index, which measures year-over-year changes in home sales activity as reported by agents, edged down to 49.1 in February, from 51.3 in January. A reading below 50 signals contraction, marking a return to declining transaction volumes after January’s expansionary reading.
    • U.S. transaction activity softened according to agents, with the sub-index slipping to 49.4 in February from 50.2 in January.
    • Canada saw a more pronounced decline, with the sub-index falling to 46.2 from 60.5 in January, its first contractionary reading since August 2024.
  • Agent Optimism Index Eases but Remains Near Recent Highs: Real’s Agent Optimism Index, which tracks agent sentiment on local market conditions over the next 12 months, registered 70.4 in February, down from 74.0 in January, though still near historic highs. Forty-eight percent (48%) of agents reported feeling more optimistic about their local market compared to the previous month, with 22% feeling significantly more optimistic. Only 9% of agents felt more pessimistic, while 22% remained neutral.
  • Market Conditions Remain Balanced, But Buyer Power is Growing: In February, 33% of agents described their market as balanced, down from 36% in January. Thirty-four percent (34%) still reported a seller’s market, unchanged from the prior month, while 33% identified a buyer’s market, up from 30% in January. This points to a gradual shift toward more buyer-friendly conditions.
  • Affordability Remains the Top Challenge for Buyers, But Economic Uncertainty is Rising: While 53% of agents cited affordability as the biggest hurdle for homebuyers—down from 61% in January—another 15% noted concerns over economic uncertainty as the biggest challenge facing homebuyers, up from 10% the prior month. Inventory constraints were noted by 24% of agents, a slight uptick from 23% in January, while buyer competition remained limited, with just 4% of agents citing it as a key issue.

Key Survey Findings: Housing Inventory Trends

  • Housing Inventory Rises in Most Markets: A majority of agents (52%) reported higher housing inventory than a year ago, with 15% citing a significant increase in their markets and 37% noting a slight rise. Meanwhile, 28% said inventory levels have remained steady, while 20% observed a decline in available listings.
  • Agents Advise More Competitive Pricing as Inventory Increases: Among agents in markets with rising inventory, 49% are advising sellers to set lower initial listing prices to reduce time on market. Twenty-two percent (22%) recommend home upgrades or professional staging to improve marketability, while 12% suggest more frequent price reductions if homes aren’t selling. Another 12% are maintaining previous pricing strategies, and 2% are recommending higher list prices to allow for more negotiation.
  • Buyers Leverage Higher Inventory to Negotiate More Aggressively: Forty-five percent (45%) of agents said they are encouraging buyers to negotiate harder on price due to increased inventory, while 24% report no major change in buyer strategy. Additionally, 13% suggest buyers take more time evaluating multiple options, and another 13% recommend buyers include more contingencies when submitting offers.
  • Homes Are Taking Longer to Sell: Approximately two-thirds (65%) of agents said homes are sitting on the market longer than this time last year, with 50% reporting a slight increase in time on market and 15% noting a more significant rise. Twenty-two percent (22%) indicated that listing times are unchanged, while only 13% of agents reported a decrease in time on market.
  • Lofty Seller Expectations Are Primary Cause of Longer Time on Market: Among agents seeing longer selling times, 41% cited unrealistic seller pricing expectations as the main cause, while 39% pointed to affordability constraints limiting buyer demand. Ten percent (10%) attributed longer market times to increased competition from other listings, 5% to outdated property features, and 1% to other property-specific challenges.

A summary presentation of these results can be found on Real’s investor relations website at the link here.

About the Survey

The Real Brokerage February 2025 Agent Survey included responses from over 500 real estate agents across the United States and Canada and was conducted between February 28, 2025 and March 11, 2025. Responses to questions regarding transaction growth and agent optimism were calibrated on a 0-100 point index scale, with readings above 50 indicating an improving trend, whereas readings below 50 indicate a declining trend. Responses are meant to capture industry-level information and are not meant to serve as an indication of Real’s company-specific growth trends. Additionally, given the smaller sample size, there can be greater variability in Canada index results on a month-to-month basis.

About Real

Real (NASDAQ: REAX) is a real estate experience company working to make life’s most complex transaction simple. The fast-growing company combines essential real estate, mortgage and closing services with powerful technology to deliver a single seamless end-to-end consumer experience, guided by trusted agents. With a presence in all 50 states throughout the U.S. and Canada, Real supports over 26,000 agents who use its digital brokerage platform and tight-knit professional community to power their own forward-thinking businesses.

Forward-Looking Information

This press release contains forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information is often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. These statements reflect management’s current beliefs and are based on information currently available to management as of the date hereof. Forward-looking information in this press release includes, without limiting the foregoing, expectations regarding the residential real estate market in the U.S. and Canada.

Forward-looking information is based on assumptions that may prove to be incorrect, including but not limited to expectations regarding 2025 market conditions. Real considers these assumptions to be reasonable in the circumstances. However, forward-looking information is subject to known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied in the forward-looking information. Important factors that could cause such differences include, but are not limited to, slowdowns in real estate markets and economic and industry downturns, and those risk factors discussed under the heading “Risk Factors” in the Company’s Annual Information Form dated March 6, 2025, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be carefully considered and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Real cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and Real assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Investor inquiries, please contact:

Ravi Jani

Vice President, Investor Relations and Financial Planning & Analysis

[email protected]

908.280.2515

For media inquiries, please contact:

Elisabeth Warrick

Senior Director, Marketing, Communications & Brand

[email protected]

201.564.4221

KEYWORDS: New York United States North America Canada

INDUSTRY KEYWORDS: Data Management Technology Residential Building & Real Estate Other Technology Construction & Property Software

MEDIA:

Logo
Logo
Posted on

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

  • Patients and Healthcare Providers Alike Call for More Innovative, Less Toxic Treatment Options
  • CRC Diagnoses Rise While Current Standards Fall Short

LEXINGTON, Mass.–(BUSINESS WIRE)–
Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorectal Cancer in Focus survey, highlighting critical unmet needs and patient priorities in colorectal cancer (CRC) care.

Colorectal cancer remains the second leading cause of cancer-related deaths worldwide and places an enormous burden on individuals, their families and loved ones, and the healthcare system alike.1 The Colorectal Cancer in Focus survey, conducted online in the U.S. from October to December 2024, gathered insights from patients and healthcare providers (HCPs) to better understand their experiences and priorities in CRC treatment.

Key Survey Insights:

  • Early-Onset CRC is on the Rise: More than half of HCPs reported an increase in CRC diagnoses among adults under 50, with 82% of surveyed patients diagnosed before that age.
  • Gaps in the Standard of Care: Nearly all surveyed HCPs (93%) believe current treatment options for CRC are insufficient, with chemotherapy remaining the dominant approach despite its debilitating side effects.
  • Rising Patient Demand for Chemotherapy Alternatives: A majority of patients highly value the possibility of treatments that do not involve chemotherapy. 61% expressed interest in new treatment options outside of chemotherapy, including immunotherapy (IO).
  • Growing Interest in Immunotherapies: While awareness of IO therapies remains low among patients, 37% of HCPs cited IO therapies as the most promising potential advancement in CRC treatment.
  • Patients Prioritize Quality of Life: In addition to extending life, approximately one in three patients identified minimal impact on quality of life as a top treatment priority. Majority cited side effects of chemotherapy and/or radiation as the most difficult aspect of their cancer journey.

Steven O’Day, MD, Chief Medical Officer at Agenus,emphasized the importance of these findings:

“This survey underscores the urgent need for transformative solutions in colorectal cancer treatment. Patients and healthcare providers alike are calling for more effective options that not only extend survival but also preserve quality of life. At Agenus, we are committed to advancing next-generation immuno-oncology therapies that have the potential to address these unmet needs and bring meaningful progress to the CRC community.”

Acknowledging Advocacy Groups for Their Partnership

Agenus extends its gratitude to the Colorectal Cancer Allianceand Fight Colorectal Cancer for their collaboration in disseminating the patient survey and amplifying the voices of those affected by CRC. Their partnership has been instrumental in uncovering these critical insights and driving advocacy for meaningful change.

“Patients facing colorectal cancer deserve treatment options that prioritize both survival and quality of life,” said Michael Sapienza, CEO of the Colorectal Cancer Alliance. “The survey findings highlight a clear need for new therapies that are targeted and minimize harsh side effects. We’re proud to partner on this effort to amplify patient voices and advocate for innovative solutions that can transform care.”

“This survey reinforces what patients have long been telling us—current colorectal cancer treatments are not enough,” said Anjee Davis, CEO of Fight Colorectal Cancer. “Too many are facing limited options, debilitating side effects, and a lack of awareness about emerging therapies. It is critical that we prioritize patient-centered innovation that not only extends survival but also improves quality of life.”

With these findings, Agenus reaffirms its commitment to developing and accelerating access to novel therapies that harness the power of the immune system. Through continued collaboration with researchers, advocacy organizations, and healthcare providers, the company aims to advance treatment innovation and improve the standard of care for CRC patients worldwide.

For more information about the Colorectal Cancer in Focus survey and Agenus’ efforts in CRC research, please visit https://agenusbio.com/colorectal-cancer-in-focus/.

1

Center for Disease Control and Prevention. Colorectal Cancer Basics. https://www.cdc.gov/colorectalcancer/about/index.html

About the Survey

The Colorectal Cancer in Focus survey was conducted online in the U.S. from October to December 2024, gathering responses from 126 patients living with CRC and 100 HCPs specializing in the disease. The HCP survey was fielded via SERMO from October 14–22, 2024, while the patient survey was distributed through SurveyMonkey and StudyKik, with support from the Colorectal Cancer Alliance and Fight Colorectal Cancer.

About Agenus

Agenus is a leading immuno-oncology company developing innovative cancer treatments. Founded in 1994, the company is committed to expanding the reach of cancer immunotherapy through novel antibody therapeutics, adoptive cell therapies (via MiNK Therapeutics), and adjuvants (via SaponiQx). With end-to-end development capabilities, including commercial and clinical cGMP manufacturing, research, and a global clinical operations footprint, Agenus is uniquely positioned to drive innovation in immuno-oncology.

Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow @agenus_bio on social media. Investor updates and key company information will be routinely posted on our website and social channels.

Forward-Looking Statement

This press release contains forward-looking statements pursuant to the safe harbor provisions of federal securities laws. These statements include references to Agenus’ botensilimab and balstilimab programs, expected regulatory timelines, and other projections. Forward-looking statements are identifiable by words such as “may,” “believes,” “expects,” “anticipates,” “hopes,” “intends,” “plans,” “forecasts,” “estimates,” “will,” “potential,” and similar expressions.

These statements are subject to risks and uncertainties that may cause actual results to differ materially. Such risks include those detailed in Agenus’ most recent Annual Report on Form 10-K (2023) and subsequent Quarterly Reports on Form 10-Q, filed with the Securities and Exchange Commission (SEC). Agenus cautions investors not to place undue reliance on forward-looking statements and undertakes no obligation to update them except as required by law.

Investor:

917-362-1370

[email protected]

Media:

781-674-4422

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Health Science Research Oncology

MEDIA:

Logo
Logo
Posted on

WPG Americas Accelerates High-Speed Connectivity Solutions through Credo Partnership

PR Newswire


SAN JOSE, Calif.
, March 19, 2025 /PRNewswire/ — WPG Americas Inc. (WPGA), a leading distributor of electronic components and supply chain services, is pleased to announce its strategic partnership with Credo, a global leader in high-performance, low-power connectivity solutions.

Credo Technology Group Holding Ltd (Credo) (NASDAQ: CRDO) specializes in delivering high-speed connectivity solutions that are designed to meet the increasing demands for bandwidth in modern networking environments. Their product lines include optical DSPs, linecard gearbox, retimer & MACsec PHYs, Chiplets, and Active Electrical Cables known for their superior performance and energy efficiency.

“Credo’s products are at the forefront of innovation,” said Chris Miller, President at WPG Americas Inc. “As demand for high-speed data transmission grows across industries, Credo’s products will enable our customers to achieve superior performance while optimizing efficiency.”

“Partnering with WPG Americas strengthens our ability to deliver high-performance, energy-efficient connectivity solutions to a broader range of customers,” said Michael Girvan Lampe, VP of Worldwide Sales & Marketing at Credo. “This collaboration ensures that businesses have access to the most advanced networking technologies available today.”

This partnership aligns with WPGA’s commitment to providing its customers with access to the latest technological innovations. The addition of Credo’s portfolio complements WPGA’s existing offerings and supports a wide range of applications across various sectors including hyperscale data centers, telecommunications, and cloud computing.

About WPG Americas Inc.

Headquartered in San Jose, CA, WPG Americas Inc. is a member of WPG Holdings, a $27.4B worldwide distributor of semiconductors, passive, electro-mechanical, and display products. Founded in November 2007, WPGA is a franchised partner for leading technology suppliers. As a member of WPG Holdings, WPGA is uniquely positioned to offer total solutions to its diverse customer base. WPGA continues to introduce new leading-edge technologies, quality service, and design-in-focus through its superior engineering programs. For more information, visit www.wpgamericas.com. You can also follow us on LinkedIn and YouTube.

About Credo
Our mission is to deliver high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. Credo is an innovator in providing reliable, secure, high-speed connectivity solutions that deliver improved power efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. Our innovations ease system bandwidth bottlenecks while simultaneously improving on power, security, and reliability. Our connectivity solutions are optimized for optical and electrical Ethernet applications, including the emerging 100G,200G, 400G, 800G and the emerging 1.6T port markets. Credo products are based on our proprietary Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies. Our product families include Integrated Circuits (ICs) for the optical and line card markets, Active Electrical Cables (AECs) and SerDes Chiplets. Our intellectual property (IP) solutions consist primarily of SerDes IP licensing.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wpg-americas-accelerates-high-speed-connectivity-solutions-through-credo-partnership-302404872.html

SOURCE WPG AMERICAS, INC.

Posted on

Entry-Level Microcontrollers Reduce System Cost and Complexity in Safety-Critical Applications

Microchip’s AVR® SD MCU family enables industry-standard functional safety compliance at a price point under a dollar

CHANDLER, Ariz., March 19, 2025 (GLOBE NEWSWIRE) — To assist engineers in meeting stringent safety requirements while minimizing design costs and complexity, Microchip Technology (Nasdaq: MCHP) has launched the AVR® SD family of microcontrollers (MCUs). The MCUs feature built-in functional safety mechanisms and are designed to support applications requiring rigorous safety assurance. Paired with a dedicated safety software framework, this is the first entry-level MCU of its kind—at this price point—designed to meet Automotive Safety Integrity Level C (ASIL C) and Safety Integrity Level 2 (SIL 2) requirements, which mandate redundant safety checks. Further enhancing the safety credentials of the AVR SD family, the MCUs follow a functional safety management system that has been certified by TÜV Rheinland.

Hardware safety features include a dual-core lockstep CPU, dual Analog-to-Digital Converters (ADCs), Error Correction Code (ECC) on all memories, a dedicated error controller module, error injection mechanisms and voltage and clock monitors. These features reduce fault detection time and software complexity. The AVR SD family has the capability to detect internal faults quickly and deterministically, allowing applications to meet stringent Fault Detection Time Interval (FDTI) targets as low as 1 millisecond, helping prevent hazardous situations and increasing reliability.

The hardware features work with Microchip’s safety framework software to manage functional safety diagnostics so the MCUs can detect and handle errors autonomously, initiating a safe state when necessary. The MCUs can be used as the main processor for crucial functions, such as detecting thermal runaways or monitoring sensor data like rotary positions, at minimal power consumption. It is also an excellent candidate for a coprocessor in complex systems to mirror or offload safety-critical functions for applications targeting higher safety integrity levels up to ASIL D and SIL 3.

“When designing safety-critical applications, engineers have typically been limited to using expensive and complicated devices. By integrating specific safety features directly into an entry-level MCU and providing a supporting software framework, we are helping our customers meet stringent safety standards with greater efficiency,” said Greg Robinson, corporate vice president of Microchip’s MCU business unit. “With the AVR SD family, designers can significantly reduce development time and minimize system and certification costs.”

The AVR SD MCUs are designed in compliance with International Organization for Standardization (ISO) 26262 and International Electrotechnical Commission (IEC) 61508 standards. Safety standards are implemented across a variety of industries such as aerospace and defense, industrial automation, automotive and medical sectors. Specific applications include flight control systems, ignition control, robotics safety functions, Advanced Drive Assistance Systems (ADAS) and medical infusion pumps. Visit Microchip’s website to learn more about the company’s full portfolio of AVR® MCUs and functional safety offerings.

Development Tools

AVR SD MCUs are compatible with the TÜV SÜD functional safety certified MPLAB® XC8 Pro compiler and Microchip’s popular Curiosity Nano development board. The MCUs are supported by functional safety packages that include safety documentation (Failure Modes, Effects and Diagnostic analysis report, Safety manual, Dependent Fault Analysis report), safety software and compliance reports.

Pricing and Availability

AVR SD MCUs start at $0.93 each in 5,000-unit quantities and with lower pricing available for higher volumes. For additional information and to purchase, contact a Microchip sales representative, authorized worldwide distributor or visit Microchip’s Purchasing and Client Services website, www.microchipdirect.com.

Resources

High-res images available through Flickr or editorial contact (feel free to publish):


About Microchip Technology

:

Microchip Technology Inc. is a leading provider of smart, connected and secure embedded control and processing solutions. Its easy-to-use development tools and comprehensive product portfolio enable customers to create optimal designs which reduce risk while lowering total system cost and time to market. The company’s solutions serve over 100,000 customers across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support along with dependable delivery and quality. For more information, visit the Microchip website at www.microchip.com.

Note: The Microchip name and logo, the Microchip logo and AVR are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. All other trademarks mentioned herein are the property of their respective companies.

Editorial Contact: Reader Inquiries:
Amber Liptai 1-888-624-7435
480-792-5047  


[email protected]

 		 



Posted on

Indero Marks 40th Study Live with Veeva RTSM

PR Newswire

Specialized CRO standardizes on Veeva RTSM to drive operational efficiency and faster study timelines


PLEASANTON, Calif.
, March 19, 2025 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Indero, formerly Innovaderm Research, successfully launched its 40th RTSM study on Veeva RTSM. By standardizing with Veeva RTSM, Indero has strengthened its clinical trial operations, harnessing advanced RTSM capabilities and expert support to drive efficiency, enhance process consistency, and streamline execution.

“As we continue to optimize our clinical trial operations, Veeva RTSM has driven more efficient processes and closer collaboration to ensure seamless execution,” said Eric Hardy, senior director, biometrics at Indero. “Because of this added speed and effectiveness, we can help bring therapies to market faster, allowing our sponsors, sites, and patients to benefit sooner.”

The launch of Indero’s 40th RTSM study highlights the continued collaboration between the two organizations. Since first adopting Veeva RTSM, Indero has worked closely with Veeva to continuously refine and implement standardized processes that drive long-term success for its clinical trials.

“With its enterprise standard RTSM approach, Indero is achieving greater long-term efficiency and reliability in their studies,” said Steve Simmerman, general manager, Veeva RTSM. “Partnering with Indero to standardize clinical processes will further accelerate study timelines, demonstrating a streamlined approach that can advance the industry.”

Additional Information
To learn more about Veeva’s enterprise standard RTSM, visit www.veeva.com/rtsm.

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Deivis Mercado

Veeva Systems
925-226-8821
[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/indero-marks-40th-study-live-with-veeva-rtsm-302405321.html

SOURCE Veeva Systems

Posted on

PIZZA HUT INTRODUCES HUTTY – YOUR SECOND-SCREEN BUDDY FOR COLLEGE BASKETBALL, BRINGING FANS TOGETHER WITH HOOPS INSIGHTS AND EXCLUSIVE REWARDS

PR Newswire

Pizza Hut’s Digital-Led Experience Enhances Game Time, Turning Solo Viewing into a Shared, Interactive Event


PLANO, Texas
, March 19, 2025 /PRNewswire/ — Pizza Hut has always been a go-to for bringing people together over great food and good times. Now, as the Official and Only Pizza Sponsor of college basketball’s biggest tournament, the brand is extending that role into the digital space with Hutty – a second-screen companion designed to enhance every game, keep fans connected, and serve up rewards all tournament long.

While fans are locked into the action, they’re also scrolling. 69% of those watching games on TV also use their mobile devices simultaneously, and 64% of avid sports fans engage with social media during the tournament*. That’s where Hutty comes in – acting as your ultimate digital sidekick. Hutty brings real-time reactions, hot takes, and exclusive Pizza Hut offers straight to fans – turning solo second-screen moments into an interactive, community-driven experience.

So, who is Hutty?

  • Your Digital Game-Time Companion – The way fans watch has changed – most are scrolling while watching. Hutty makes that experience better by reacting to buzzer-beaters, dropping fun insights, and keeping fans entertained from tip-off to the final whistle.
  • The Ultimate College Basketball Fan – Hutty is passionate, fun, and all about the game. He lives for upsets, believes in game-day superstitions, and knows that pizza is the ultimate fuel for every matchup.
  • Your Second-Screen Sidekick – Just like we fuel watch parties, Hutty is bringing people together digitally, making sure every game – whether watched alone or with friends – feels more connected and fun. Whether he’s dishing out discount codes, dropping hot takes, or simply sharing in the highs and lows of the tournament, he’s there to make every moment more interactive.
  • The Gateway to Exclusive Rewards – Talking with Hutty isn’t just fun – it might just pay off. Fans will have the chance to win:

    • Free Pizza for a Year – A few lucky fans will win free pizza for an entire year.
    • Surprise Pizza Deals – Discount codes, BOGO offers, and free sides.
    • Limited-Edition Pizza Hut Swag – Engage with Hutty for a chance to win.

“Basketball’s biggest tournament is a time when fans are more engaged than ever, but many are watching alone,” said Melissa Friebe, Chief Marketing Officer of Pizza Hut. “Pizza Hut has always been about bringing people together, and now, with Hutty, we’re extending that experience into the digital space – turning every game into a shared moment, no matter where or how you’re watching.”

Kicking off at the start of the tournament, fans can chat with Hutty by going to @PizzaHut on Instagram and tapping on Hutty. Fans can enter the sweepstakes by signing up at PizzaHutsHuttySweeps.com, where they’ll have the chance to win big**.

For more information, visit PizzaHutsHuttySweeps.com or follow @PizzaHut on Instagram.

* Sources: MarketingDive.com, Statista March 2023 Survey

**NO PURCHASE NECESSARY. Void where prohibited. Open to legal residents of the 50 US and DC who are 18 years of age or older. The Pizza Hut March Madness 2025 Sweepstakes starts at 6:00 pm ET on 3/19/25 and ends at 11:30 pm ET on 4/8/25. Sponsored by Pizza Hut, LLC. For rules, visit PizzaHutsHuttySweeps.com

About Pizza Hut®

Pizza Hut, a subsidiary of Yum! Brands, Inc. (NYSE: YUM), was founded in 1958 in Wichita, Kansas and since then has earned a reputation as a trailblazer in innovation with the creation of icons like Original® Pan and Original® Stuffed Crust pizzas. In 1994, Pizza Hut pizza was the very first online food order. Today, Pizza Hut continues leading the way in the digital and technology space with over half of transactions worldwide coming from digital orders. Pizza Hut is committed to providing an easy pizza experience – from order to delivery – and has Hut Rewards®, the Pizza Hut loyalty program that offers points for every dollar spent on food any way you order. Hut Rewards is open to U.S. residents 18+. See applicable terms at https://hutrewards.pizzahut.com/terms/. A global leader in the pizza category, Pizza Hut operates more than 19,000 restaurants in more than 100 countries. Through its enormous presence, Pizza Hut works to unlock opportunity for its team members and communities around the world.

For more information, visit www.pizzahut.com. You can remain up to date on what’s happening at Pizza Hut by following us on Facebook, Twitter, Instagram, TikTok and subscribing to our YouTube channel.

Press Contact
ALISON BROD MARKETING + COMMUNICATIONS
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pizza-hut-introduces-hutty–your-second-screen-buddy-for-college-basketball-bringing-fans-together-with-hoops-insights-and-exclusive-rewards-302405274.html

SOURCE Pizza Hut

Posted on

R-V Industries’ to Participate in Several Upcoming Industry Events

HONEY BROOK, Pa., March 19, 2025 (GLOBE NEWSWIRE) — R-V will be participating in several upcoming industry events. Ackley, Beta Star, Genesis, and R.W. Hartnett will be exhibitors at the Interphex trade show April 1-3 in New York City. Ackley and R.W. Hartnett will be exhibiting at the CPHI show October 28-30 in Frankfurt, Germany. Having four of its brands at the world’s biggest pharma-centric trade shows demonstrates R-V’s emergence as a significant player across the pharmaceutical landscape and is indicative of a company-wide commitment to manufacturing excellence, regardless of the industry.

Market and product diversity has been a key differentiator of R-V Industries over its 51-year history. Fabricated steel products established R-V as an innovator in the Customer Fabrication, ASME Code Pressure Vessel, Nuclear, Paper, and Power markets since its founding in 1974. 

“Our vision is to grow and diversify end markets and find specific niches where our innovative products, facilities, quality, and service create value for customers and growth opportunities for our employees,” said Kirk A. Putt, president and CEO of R-V. The Pharmaceutical market was one the company had been targeting.

The opportunity to enter the Pharmaceutical, Life Science, and University Research markets materialized with the acquisition of Beta Star Life Science Equipment in 2007, a former customer of R-V’s. This acquisition expanded the identity of R-V, from a successful small business focused on industrial processing equipment to a global brand. 

​R-V and Beta Star were a natural fit, for many years R-V manufactured the ASME pressure chambers utilized on Beta Star autoclaves. R-V’s ASME Code division continues to manufacture chambers, reactors, tanks, and other stainless steel pressure vessels for pharmaceutical clients. By bringing Beta Star in-house, it allowed R-V to engineer new products while optimizing manufacturing processes.

A series of acquisitions in the pharmaceutical industry followed, starting with Genesis Packaging Technologies (2017), now widely recognized as a worldwide leader in high-speed vial capping and residual seal force testing. 

“Genesis is a great example of how we operate as a series of small companies outperforming larger competitors by providing the highest performing equipment in the industry and dynamic customer service,” said Putt.

​MBC Aerosol (Elgin, IL) was acquired in 2022. MBC provides aerosol/bag-on-valve filling and packaging lines for pharmaceutical and consumer goods.

In June of 2023, R-V acquired Ackley Machine Corporation (Moorestown, NJ), a leader in pharmaceutical printing, laser marking, and laser drilling. This deal expanded R-V’s international customer base with the opportunity to work with leading global pharmaceutical brands.

Less than a year later, R-V would acquire the longest tenured company in the pharmaceutical printing and laser marking market, R.W. Hartnett (Philadelphia), founded in 1880.

R-V now features six divisions working in pharmaceutical and ancillary markets, generating over 30% of its $100mm annual revenue. These groups collaborate and share resources to innovate and service customer needs.

About R-V Industries

Founded in 1974, R-V Industries is a leading industrial equipment supplier. R-V’s industrial equipment solutions help produce many well-known consumer products and services, creating a better life for people around the world. With over 350 employees, R-V serves a diverse set of customers across biotechnology, chemical, consumer goods, food & beverage, life sciences, nuclear waste, oil & gas, paper & pulp, pharmaceutical, and power generation industries.

R-V Industries is a portfolio company of Prospect Capital Corporation (NASDAQ: PSEC), a publicly traded business development company with $7.2 billion of total assets as of December 31, 2024. Prospect has provided capital to help complete R-V’s recent acquisitions.

For further information, contact:

Kirk A. Putt ([email protected])